

# Lakeshore Hospital Price

Unlisted Share Financial Report - ISIN INE01TI01010

## Company Overview

VPS Lakeshore Hospital, Kochi, is a multi-specialty tertiary care hospital providing comprehensive services across cardiology, oncology, gastro sciences, neurosciences, orthopedics and transplants. The facility includes advanced ICUs, operating theaters, diagnostics and a blood bank, supported by 24x7 emergency care. Company materials reference NABH accreditation, transplant programs and a focus on clinical outcomes. As part of VPS Healthcare, the hospital integrates international protocols and digital systems for appointments, records and patient support, serving Kerala and international medical travelers with multidisciplinary care.

## Market Snapshot

CURRENT PRICE / SHARE <b>Rs 110.19</b>	MARKET CAP <b>1.10K Cr</b>	P/E RATIO <b>27.18</b>	P/B RATIO <b>2.45</b>
BOOK VALUE / SHARE <b>Rs 43.2</b>	FACE VALUE <b>Rs 10</b>	52 WEEK HIGH <b>Rs 120.75</b>	52 WEEK LOW <b>Rs 108.9</b>
DEBT TO EQUITY <b>0.00</b>	RETURN ON EQUITY <b>9.24%</b>	LOT SIZE <b>500 shares</b>	TOTAL SHARES <b>10,00,00,000</b>

Prices are indicative over-the-counter levels as of 07 July 2026. Actual deal prices may vary.

## Corporate Details

ISIN	<b>INE01TI01010</b>
CIN	<b>U85110KL1996PLC010260</b>
PAN	<b>AAACL4923A</b>
Registrar (RTA)	<b>Integrated Registry Management Services</b>
Depository	<b>NSDL &amp; CDSL</b>
Sector	<b>Health Care</b>
Industry	<b>Hospitals &amp; Healthcare Services</b>

## Income Statement (Rs Crore)

Particulars	2022	2023	2024	2025
<b>Revenue</b>	<b>359</b>	<b>419</b>	<b>396</b>	<b>408</b>
Cost of Material Consumed	102	112	111	117
Change in Inventory	-2	-2	2	-0.2
Gross Margins	72.14%	73.75%	71.46%	71.37%
Employee Benefit Expenses	63	64	75	79
Other Expenses	113	143	135	141
<b>EBITDA</b>	<b>83</b>	<b>102</b>	<b>73</b>	<b>71.2</b>
OPM	23.12%	24.34%	18.43%	17.45%
Other Income	3	5	7	8.23
Finance Cost	2	2	1	0.3
Depreciation & Amortisation	22	23	24	26
<b>EBIT</b>	<b>61</b>	<b>79</b>	<b>49</b>	<b>45.2</b>
EBIT Margins	16.99%	18.85%	12.37%	11.08%
<b>Profit Before Tax</b>	<b>62</b>	<b>82</b>	<b>55</b>	<b>53</b>
PBT Margins	17.27%	19.57%	13.89%	12.99%
Tax	18	25	11	14
<b>Profit After Tax</b>	<b>44</b>	<b>57</b>	<b>44</b>	<b>39</b>
Net Profit Margin	12.26%	13.6%	11.11%	9.56%
EPS	Rs 4.4	Rs 5.7	Rs 4.4	Rs 3.9

## Balance Sheet - Assets (Rs Crore)

Particulars	2022	2023	2024	2025
Fixed Assets	340	328	347	343
Capital Work in Progress	0	5	2	4.6
Investments	0	0	0	0
Trade Receivables	20	20	27	34
Inventory	11	13	11	11
Other Assets	93	134	121	140.4
<b>Total Assets</b>	<b>464</b>	<b>500</b>	<b>508</b>	<b>533</b>

## Balance Sheet - Liabilities (Rs Crore)

Particulars	2022	2023	2024	2025
Share Capital	100	100	100	100
Face Value	Rs 10	Rs 10	Rs 10	Rs 10
Reserves	231	273	300	322
Borrowings	19	13	0	0
Trade Payables	33	34	33	39
Other Liabilities	81	80	75	72
<b>Total Liabilities</b>	<b>464</b>	<b>500</b>	<b>508</b>	<b>533</b>

## Cash Flow Statement (Rs Crore)

Particulars	2022	2023	2024	2025
<b>Profit Before Tax</b>	<b>59</b>	<b>82</b>	<b>55</b>	<b>53</b>
Operating Profit Before Working Capital	87	114	74	74
Change in Receivables	-56	-29	-13	2.9
Change in Inventories	-2	-2	2	-0.2
Change in Payables	12	-9	0	4.29
Other Changes	0	1	0	0.44
Working Capital Change	-46	-39	-11	7.43
Cash Generated From Operations	41	75	63	81.43
Tax	-10	-20	-19	-13.12
<b>Cash Flow From Operations</b>	<b>31</b>	<b>55</b>	<b>44</b>	<b>68.31</b>
Purchase of PPE	-26	-9	-46	-22.6
Sale of PPE	1	0.1	0.5	0
<b>Cash Flow From Investment</b>	<b>-24</b>	<b>-6.9</b>	<b>-39</b>	<b>-15.8</b>
Borrowing	-18	-6	-13	0
Dividend	-5	-15	-17	-17
Equity	0	0	0	0
Others From Financing	-3	-2	-2	-1
<b>Cash Flow from Financing</b>	<b>-26</b>	<b>-23</b>	<b>-32</b>	<b>-18</b>
<b>Net Cash Generated</b>	<b>-19</b>	<b>25.1</b>	<b>-27</b>	<b>34.51</b>
Cash at the Start	31	12	37	9.93
Cash at the End	12	37.1	10	44.44

## Key Ratios

Particulars	2022	2023	2024	2025
Operating Profit Margin	23.12%	24.34%	18.43%	17.45%
Net Profit Margin	12.26%	13.6%	11.11%	9.56%
Earning Per Share (Diluted)	Rs 4.4	Rs 5.7	Rs 4.4	Rs 3.9

Source: Compiled by Neoma Capital research. Data as of FY2025. Figures may be restated in subsequent filings.